Actinium Pharmaceuticals
ATNM
48 hedge funds and large institutions have $15.6M invested in Actinium Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 14 increasing their positions, 5 reducing their positions, and 9 closing their positions.
180% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 5
78% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 9
17% more funds holding
Funds holding: 41 → 48 (+7)
17% more call options, than puts
Call options by funds: $3.16M | Put options by funds: $2.7M
2.81% less ownership
Funds ownership: 17.56% → 14.75% (-2.8%)
32% less capital invested
Capital invested by funds: $23.1M → $15.6M (-$7.48M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$2.58M |
| 2 |
D.E. Shaw & Co
New York
|
+$697K |
| 3 |
Millennium Management
New York
|
+$598K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$590K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
+$356K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$7.66M |
| 2 |
SCM
Sio Capital Management
New York
|
-$1.83M |
| 3 |
JGC
J. Goldman & Co
New York
|
-$1.64M |
| 4 |
Morgan Stanley
New York
|
-$331K |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$276K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
51
Tower Research Capital (TRC)
New York
| – | -$14K | -1,481 | Closed |
|
52
Citigroup
New York
| – | -$10K | -1,005 | Closed |
|
|
AF
53
Allworth Financial
Folsom,
California
| – | -$1K | -120 | Closed |
|
ATNM Hedge Fund Activity: Q4 2020 in Review
48 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Actinium Pharmaceuticals (ATNM) for Q4 2020, worth a combined $15.6M — down 32% from $23.1M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new ATNM positions and 9 closed out — a net gain of 7 holders — while 14 added to existing stakes and 5 trimmed.
The largest buyer was Rubric Capital Management (New York), adding an estimated $2.58M. The largest seller was Consonance Capital Management, cutting an estimated $7.66M.
- 48 institutional investors held Actinium Pharmaceuticals (ATNM) as of Q4 2020, up from 41 in Q3 2020.
- Funds reported $15.6M of Actinium Pharmaceuticals stock for Q4 2020, down 32% quarter-over-quarter.
- 16 funds opened new Actinium Pharmaceuticals positions in Q4 2020 and 9 closed out, a net change of +7 holders.
- The largest Actinium Pharmaceuticals buyer in Q4 2020 was Rubric Capital Management (New York), an estimated $2.58M added.
- The largest Actinium Pharmaceuticals seller in Q4 2020 was Consonance Capital Management, an estimated $7.66M sold.
Based on aggregated 13F filings for Q4 2020.